article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. share of global pharma revenues, according to analysts Statistica 1. In 2022, the continent held a 22.4%

Drugs 147
article thumbnail

Women in Stem with Lidia Pieri

Drug Target Review

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. Identifying new drugs is an extremely complex project.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

As such, the synthesis of DNA oligonucleotides for routine molecular biology applications is often outsourced to service provider companies that operate DNA synthesisers to meet these demands. . We are even seeing some companies going completely ‘lab-free’, outsourcing the entire workflow,” says Dr Leproust. “By

DNA 246
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. Having a combination of computational skills & scientific knowledge such as molecular biology, genomics is also important.

article thumbnail

What it takes to make cancer research more inclusive

Drug Discovery World

In recent years, governments, institutes, pharma companies, and funding bodies have taken significant measures to proactively address cancer disparities. However, these social categories are rather arbitrary and don’t necessarily correspond to the underlying molecular biology of the patient, risking misguided clinical care.

Research 130
article thumbnail

Scaling Phage Therapy

Codon

3 Another considerable obstacle to pharmaceutical companies’ interest (and investment) is the fact that for a product to be patentable — and therefore profitable — it has to be considered new and inventive. ” “Somebody’s just got to break through with good data, even if it’s not us.

Therapies 138